Therefore, we suggest that XXXT can inhibit the PI3K-AKT signaling pathway in NSCLC by targeting CCNA2, FOSL2, and BIRC5 (Figure 8). This evidence concerns the gene AKT1 and non-small cell lung carcinoma.